Oncolytic Virus M1-c6v1 clinical trials
Also written VRT106.
How each study uses Oncolytic Virus M1-c6v1 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Oncolytic Virus M1-c6v1 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- VRT106
- 6
Studies by the year they started
8 studies that test it; most in 2025 (3)
| Year | Studies |
|---|---|
| 2024 | 2 |
| 2025 | 3 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 2
Guangzhou Virotech Pharmaceutical Co., Ltd. (6) · Guangdong Provincial People's Hospital (1) · Xiangya Hospital of Central South University (1)
Often tested with
Tested in the same studies.
Doxorubicin (1) · Antineoplastic Agents (1) · Camrelizumab (1) · Apatinib (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Oncolytic Virus M1-c6v1.
- Sep 2027A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid TumorsPhase 1 · Guangzhou Virotech Pharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses Oncolytic Virus M1-c6v1 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of VRT106 in Combination With Radiotherapy in Adult Patients With Diffuse Midline Glioma / Diffuse Intrinsic Pontine GliomaRecruitingPhase 2Guangzhou Virotech Pharmaceutical Co., Ltd.NCT07589257Written as VRT106 for injection
- A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCCRecruitingPhase 2/3Guangzhou Virotech Pharmaceutical Co., Ltd.NCT07589244Written as VRT106
- A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid TumorsRecruitingPhase 1Guangzhou Virotech Pharmaceutical Co., Ltd.NCT06368921Written as VRT106
- A Study of VRT106 for Injection in Patients With Recurrent/Progressive GlioblastomaRecruitingPhase 1/2Guangzhou Virotech Pharmaceutical Co., Ltd.NCT07093814Written as VRT106
- A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1Guangzhou Virotech Pharmaceutical Co., Ltd.NCT06046742Written as M1-c6v1
- A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1Guangzhou Virotech Pharmaceutical Co., Ltd.NCT06826313Written as VRT106
- Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled TrialNot yet recruitingPhase 2Guangdong Provincial People's HospitalNCT07486310Written as VRT106
- A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic CancerNot yet recruitingPhase 1/2Xiangya Hospital of Central South UniversityNCT06866977Written as Oncolytic virus VRT106